Form 8-K - Current report:
SEC Accession No. 0001651308-22-000156
Filing Date
2022-08-30
Accepted
2022-08-30 16:09:21
Documents
13
Period of Report
2022-08-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20220830.htm   iXBRL 8-K 43309
2 EX-99.1 ax30aug2022xex991xstaraddi.htm EX-99.1 20220
  Complete submission text file 0001651308-22-000156.txt   209428

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20220830.xsd EX-101.SCH 1984
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20220830_lab.xml EX-101.LAB 25070
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20220830_pre.xml EX-101.PRE 13105
7 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20220830_htm.xml XML 11914
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 221214615
SIC: 2834 Pharmaceutical Preparations